Thermo Fisher Scientific Strengthens Anatomical Pathology Portfolio with Acquisition of Raymond A. Lamb

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has acquired Raymond A. Lamb Ltd., a manufacturer of histology and anatomical pathology products based in Eastbourne, U.K., near London.

“This acquisition brings new-generation systems that can be integrated with our existing portfolio of anatomical pathology equipment and consumables to create a more efficient, and reliable, workflow.”

In business since 1964, Raymond A. Lamb has grown to become a global provider of products for the pathology laboratory. Recently, its focus has been on systems that automate the labeling and tracking of slides and cassettes that carry patient tissue samples, reducing the possibility of errors during their processing, storage and retrieval. The company has had a longstanding relationship with the anatomical pathology business of Thermo Fisher as a supplier of labeling products for cassettes and glass slides, as well as other anatomical pathology equipment.

“Our anatomical pathology customers – in both clinical and research markets – are demanding better solutions for tracking the increasing number of samples that they need to process and diagnose,” said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific. “This acquisition brings new-generation systems that can be integrated with our existing portfolio of anatomical pathology equipment and consumables to create a more efficient, and reliable, workflow.”

Raymond A. Lamb had revenues of approximately $9 million in 2007, and will be integrated into Thermo Fisher’s Analytical Technologies Segment.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 27, 2008, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission (SEC) and available in the “Investors” section of our Website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; general worldwide economic conditions and related uncertainties; use and protection of intellectual property; dependence on customers’ capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; the effect of changes in governmental regulations; the effect of exchange rate fluctuations on international operations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.